Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer

BJU International

Volumn 106, Issue 11, 2010, Pages 1623-1627

  Caso, Jorge R ^a   Tsivian, Matvey ^a   Mouraviev, Vladimir ^a   Polascik, Thomas J ^a   Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

neoplasm staging; prostate cancer; PSA; recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; UNIVARIATE ANALYSIS;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 78649267821     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09439.x     Document Type: Article

References (20)

1. Han M, Walsh PC, Partin AW, Rodriguez R,. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. J Urol 2000; 164: 89 - 92
2. Chun FK, Briganti A, Lebeau T, et al. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol 2006; 49: 273 - 8; discussion 278-9
3. DeCastro GJ, McCann T, Benson MC, McKiernan JM,. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy. Urology 2008; 72: 1214 - 8
4. Freedland SJ, Partin AW, Epstein JI, Walsh PC,. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 2004; 100: 1646 - 9
5. Hong SK, Han BK, Chung JS, et al. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int 2008; 102: 1092 - 6
6. May F, Hartung R, Breul J,. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int 2001; 88: 702 - 7
7. Van Oort IM, Witjes JA, Kok DE, Kiemeney LA, Hulsbergen-Van De Kaa CA,. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system. BJU Int 2008; 102: 438 - 41
8. Kordan Y, Chang SS, Salem S, et al. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol 2009; 182: 2291 - 5
9. Prostate. In, Green, et al. eds. American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th edn. New York, NY: Springer, 2002: 337 - 45
10. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H,. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872 - 6
11. 3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology 1998; 52: 631 - 6
12. Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005; 23: 7546 - 54
13. Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ,. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol 2008; 180: 571 - 6; discussion 576
14. Tanaka M, Suzuki N, Nakatsu H, Murakami S, Matsuzaki O, Shimazaki J,. Significance of capsular attachment and invasion of cancer tissues in prostate cancer. Int J Urol 2003; 10: 309 - 14
15. Eichelberger LE, Cheng L,. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 2004; 100: 2573 - 6
16. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V,. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 2008; 68: 1380 - 6
17. Mouraviev V, Sun L, Madden JF, Mayes JM, Moul JW, Polascik TJ,. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology 2007; 70: 1141 - 5
18. Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW,. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 2008; 11: 371 - 6
19. Ramos CG, Roehl KA, Antenor JA, Humphrey PA, Catalona WJ,. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 2004; 172: 137 - 40
20. Tsivian M, Sun L, Mouraviev V, et al. Changes in Gleason Score grading and their effect in predicting outcome after radical prostatectomy. Urology 2009; 74: 1090 - 3